Insmed Total Cost of Revenue increased by 7.2% to $47.42M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 122.9%, from $21.28M to $47.42M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 29.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.84M | $10.18M | $13.29M | $12.19M | $16.40M | $13.47M | $13.07M | $13.83M | $16.59M | $16.71M | $18.44M | $17.46M | $20.96M | $21.17M | $26.15M | $21.28M | $28.08M | $29.37M | $44.22M | $47.42M |
| QoQ Change | — | -6.0% | +30.5% | -8.3% | +34.5% | -17.8% | -3.0% | +5.8% | +20.0% | +0.7% | +10.4% | -5.3% | +20.1% | +1.0% | +23.5% | -18.6% | +31.9% | +4.6% | +50.6% | +7.2% |
| YoY Change | — | — | — | — | +51.3% | +32.3% | -1.6% | +13.4% | +1.2% | +24.0% | +41.1% | +26.2% | +26.3% | +26.7% | +41.8% | +21.9% | +33.9% | +38.7% | +69.1% | +122.9% |
| Segment | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $13.78M | $16.39M | $16.39M | $16.39M | $16.39M | $17.46M | $20.96M | $21.17M |
| Total | $13.07M | $13.83M | $16.59M | $16.71M | $18.44M | $17.46M | $20.96M | $21.17M |